

Carrie A Thompson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4558716/carrie-a-thompson-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167
papers

1,893
citations

22
h-index

41
g-index

171
ext. papers

2,344
ext. citations

3.6
avg, IF

4.16
L-index

#	Paper	IF	Citations
167	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.. <i>JCO Oncology Practice</i> , 2022 , OP2100789	2.3	
166	Changes in Frequency of Surveillance Imaging of Survivors of Diffuse Large B-Cell Lymphoma After the American Society of Hematology Choosing Wisely Recommendations. <i>JCO Oncology Practice</i> , 2021 , 17, e490-e496	2.3	
165	Assessment of Discrimination, Bias, and Inclusion in a United States Hematology and Oncology Fellowship Program. <i>JAMA Network Open</i> , 2021 , 4, e2133199	10.4	2
164	Central Nervous System Involvement By Mantle Cell Lymphoma. <i>Blood</i> , 2021 , 138, 2426-2426	2.2	0
163	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021 , 138, 1452-1452	2.2	
162	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021 , 149, 535-545	7.5	0
161	Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. <i>Supportive Care in Cancer</i> , 2021 , 29, 5293-5301	3.9	4
160	Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma. <i>Pharmacotherapy</i> , 2021 , 41, 430-439	5.8	2
159	Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021 , 96, 599-605 ⁷¹		1
158	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19547-e19547	2.2	0
157	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7542-7542	2.2	
156	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e13569-e13569	2.2	0
155	Insurance status and survival in diffuse large B-cell lymphoma: A National Cancer Database study before and after the Affordable Care Act.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6539-6539	2.2	
154	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7522-7522	2.2	1
153	A pilot study of individualized exercise prescription to improve physical activity in cancer survivors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e24030-e24030	2.2	
152	Outcomes in mantle cell lymphoma with central nervous system involvement.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e19527-e19527	2.2	0
151	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. <i>American Journal of Hematology</i> , 2021 , 96, 979-988	7.1	1

150	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021 , 96, 945-953	7.1	2
149	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2671-2678	1.9	0
148	Incidence of <i>Pneumocystis jirovecii</i> pneumonia utilizing a polymerase chain reaction-based diagnosis in patients receiving bendamustine. <i>Cancer Medicine</i> , 2021 , 10, 5120-5130	4.8	1
147	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021 , 127, 3390-3402	6.4	5
146	The association of health behaviors with quality of life in lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2021 , 62, 271-280	1.9	2
145	Testicular FDG-PET/CT uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021 , 96, E81-E83	7.1	0
144	Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function. <i>Clinical and Translational Science</i> , 2021 , 15, 105	4.9	1
143	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021 , 39, 658-663	1.3	1
142	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021 , 195, 210-216	4.5	5
141	Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. <i>JCO Oncology Practice</i> , 2021 , 17, e1382-e1393	2.3	0
140	Medical Education Interest, Exposure, and Career Planning in Subspecialty Trainees. <i>Medical Science Educator</i> , 2020 , 30, 1011-1014	0.7	
139	Incidence, clinical presentation, and outcomes of pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2622-2629	1.9	2
138	Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e005984	5.8	6
137	Body Mass Index and Survival of Patients with Lymphoma. <i>Blood</i> , 2020 , 136, 2-3	2.2	
136	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020 , 136, 21-22	2.2	
135	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2020 , 136, 36-37	2.2	
134	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020 , 136, 7-8	2.2	
133	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. <i>Blood</i> , 2020 , 136, 15-16	2.2	

132	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020 , 136, 44-45	2.2	
131	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020 , 188, 394-403	4.5	23
130	Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. <i>Journal of Cancer Survivorship</i> , 2020 , 14, 316-321	5.1	1
129	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281	7.1	18
128	Parental health in fellowship trainees: Fellows' satisfaction with current policies and interest in innovation. <i>Women's Health</i> , 2020 , 16, 1745506520949417	3	2
127	Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 156, 103093	7	3
126	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2975-2979	1.9	1
125	Non-Hodgkin lymphoma presenting as acute pancreatitis: A rare occurrence. <i>Clinical Case Reports (discontinued)</i> , 2019 , 7, 107-109	0.7	1
124	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019 , 186, 820-828	4.5	9
123	The Future of Wearable Technologies and Remote Monitoring in Health Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 115-121	7.1	27
122	Impact of lymphoma survivorship clinic visit on patient-centered outcomes. <i>Journal of Cancer Survivorship</i> , 2019 , 13, 344-352	5.1	3
121	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 786-793	7.1	10
120	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019 , 37, 144-152	2.2	80
119	Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life. <i>Blood</i> , 2019 , 134, 794-794	2.2	8
118	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019 , 134, 4306-4306	2.2	3
117	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). <i>Blood</i> , 2019 , 134, 400-400	2.2	2
116	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019 , 134, 69-69	2.2	3
115	Impact on survival of surveillance imaging after first remission in follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7536-7536	2.2	2

114	Incidence and Outcomes of Pneumocystis pneumonia When Utilizing PCR-Based Diagnosis in Patients with Hodgkin Lymphoma Receiving Intensive Chemotherapy. <i>Blood</i> , 2019 , 134, 4052-4052	2.2	0
113	Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 2896-2896	2.2	1
112	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019 , 134, 5215-5215	2.2	1
111	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019 , 134, 422-422	2.2	1
110	Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate. <i>Blood</i> , 2019 , 134, 1621-1621	2.2	1
109	Use of Imaging During Staging and Surveillance of Localized Colon Cancer in a Large Insured Population. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1355-1361	7.3	1
108	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 5293-5293	2.2	1
107	Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1232-1239	4.7	2
106	Characterization of a cryptic rearrangement in a case of mantle cell lymphoma with negative FISH studies. <i>Blood Advances</i> , 2019 , 3, 1298-1302	7.8	11
105	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. <i>Clinical Epidemiology</i> , 2019 , 11, 987-996	5.9	3
104	Identification of Factors Associated with Hematology-Oncology Fellow Academic Success and Career Choice. <i>Journal of Cancer Education</i> , 2019 , 34, 1219-1224	1.8	5
103	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018 , 93, 57-68	7.5	37
102	Building a Healthy Body After Cancer: Young Adult Lymphoma Survivors' Perspectives on Exercise After Cancer Treatment. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018 , 7, 217-229	2.2	4
101	47-Year-Old Woman With Anemia and Thrombocytopenia. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 108-112	6.4	1
100	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018 , 59, 695-701	1.9	9
99	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 187-194	7.1	45
98	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018 , 183, 149-152	4.5	3
97	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018 , 8, 73	7	19

96	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 1384-1393	7.1	15
95	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018 , 36, 749-756	1.3	10
94	Association of Health Behaviors and Quality of Life in Lymphoma Survivors. <i>Blood</i> , 2018 , 132, 4838-4838	2.2	1
93	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018 , 132, 4204-4204	2.2	1
92	Changes in Imaging Surveillance of Diffuse Large B-Cell Lymphoma Survivors after Publication of the American Society of Hematology Choosing Wisely [®] Recommendations. <i>Blood</i> , 2018 , 132, 618-618	2.2	1
91	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10042-10042	2.2	1
90	Patient-reported outcomes, emoji, and activity measured on the Apple Watch in cancer patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6501-6501	2.2	3
89	Development of novel emoji scale to measure patient-reported outcomes in cancer patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 174-174	2.2	4
88	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. <i>Blood</i> , 2018 , 132, 5401-5401	2.2	1
87	Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 3579-3579	2.2	
86	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018 , 70, 1088-1090	2.8	3
85	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018 , 93, 1543-1550	7.1	8
84	Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function. <i>Case Reports in Hematology</i> , 2018 , 2018, 7169897	0.7	5
83	Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis. <i>Leukemia and Lymphoma</i> , 2017 , 58, 457-460	1.9	2
82	66-Year-Old Woman With Falls and Confusion. <i>Mayo Clinic Proceedings</i> , 2017 , 92, e15-e19	6.4	2
81	Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 515-525	4.4	9
80	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. <i>JAMA Oncology</i> , 2017 , 3, 1257-1265	13.4	82
79	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017 , 46, 1753-1754	7.8	35

78	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017 , 4, e000187	4.6	10
77	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017 , 179, 50-60	4.5	37
76	Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis. <i>Blood</i> , 2017 , 130, 917-917	2.2	4
75	What are patients' biggest concerns? A patient reported outcome case-management system.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6572-6572	2.2	2
74	Psychosocial distress in lymphoma survivors at 3 years' follow-up.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 193-193	2.2	
73	Building a healthy body after cancer: Results of a focus group with young adult survivors to inform an intervention for exercise after treatment.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 164-164	2.2	
72	Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 151-7	4	2
71	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016 , 128, 1104-1104	2.2	1
70	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1874-1874	2.2	2
69	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016 , 128, 3034-3034	2.2	4
68	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016 , 128, 5299-5299	2.2	1
67	A patient-reported outcome driven case management system for hematology/oncology patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e18035-e18035	2.2	
66	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7552-7552	2.2	1
65	Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e19067-e19067	2.2	
64	Participation in clinical trials to improve outcomes of patients with relapsed lymphoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7523-7523	2.2	
63	Acute care use among women receiving adjuvant chemotherapy for breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6543-6543	2.2	
62	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016 , 128, 3036-3036	2.2	
61	Survival Trends in Young Patients with Waldenström Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016 , 128, 1810-1810	2.2	

60	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , 2016 , 128, 107-107	2.2	
59	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016 , 91, 179-84	7.1	30
58	Spur cell anemia in the setting of progressive liver allograft failure. <i>American Journal of Hematology</i> , 2016 , 91, 1061	7.1	2
57	Transition of Care for Inpatient Hematology Patients Receiving Chemotherapy: Development of Hospital Discharge Huddle Process and Effects of Implementation. <i>Journal of Oncology Practice</i> , 2016 , 12, e88-94	3.1	7
56	PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016 , 17, 24	5.4	9
55	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016 , 91, 1096-1101	7.1	137
54	Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy. <i>American Journal of Hematology</i> , 2016 , 91, 1113-1117	7.1	17
53	Symptom burden and integrative medicine in cancer survivorship. <i>Supportive Care in Cancer</i> , 2015 , 23, 2989-94	3.9	19
52	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2365-72	1.9	2
51	Toxoplasmosis in patients with hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2015 , 56, 536-8	1.9	7
50	Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2015 , 56, 434-9	1.9	12
49	Clozapine therapy throughout myelosuppressive chemotherapy: regulations without standardization. <i>Psycho-Oncology</i> , 2015 , 24, 1581-5	3.9	5
48	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015 , 6, 5751	17.4	44
47	Reply to V. Pitini et al and L.J. Costa. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1625-6	2.2	3
46	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015 , 126, 2683-2683	2.2	4
45	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015 , 126, 3992-3992	2.2	1
44	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015 , 126, 3730-3730	2.2	
43	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015 , 126, 2490-2490	2.2	

42	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 1501-1501	2.2	
41	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015 , 126, 3317-3317	2.2	
40	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015 , 126, 4993-4993	2.2	
39	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015 , 126, 1456-1456	2.2	
38	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014 , 46, 1233-8	36.3	108
37	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. <i>American Journal of Human Genetics</i> , 2014 , 95, 462-71	11	74
36	Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3506-12	2.2	118
35	Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1066-73	2.2	220
34	Breast cancer survivors' self-reported needs and preferences of survivorship care. <i>Breast Journal</i> , 2014 , 20, 107-9	1.2	8
33	A unifying diagnosis for pancytopenia, fever, hypoglycemia, and lactic acidosis. <i>American Journal of Hematology</i> , 2013 , 88, 78-81	7.1	2
32	End-of-life care in a population-based cohort of cancer patients: clinical trial participation versus standard of care. <i>BMJ Supportive and Palliative Care</i> , 2013 , 3, 181-7	2.2	6
31	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 290-7	1.9	36
30	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013 , 122, 362-362	2.2	2
29	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. <i>Blood</i> , 2013 , 122, 1703-1703	2.2	
28	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013 , 122, 4306-4306	2.2	
27	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012 , 120, 1540-1540	2.2	1
26	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. <i>Blood</i> , 2012 , 120, 1525-1525	2.2	
25	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). <i>Blood</i> , 2012 , 120, 1527-1527	2.2	

24	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (–) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. <i>Blood</i> , 2012 , 120, 1604-1604	2.2	1
23	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012 , 120, 684-684	2.2	
22	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012 , 120, 149-149	2.2	
21	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012 , 120, 1563-1563	2.2	
20	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2012 , 120, 1573-1573	2.2	
19	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. <i>Blood</i> , 2012 , 120, 2634-2634	2.2	
18	Care of the adult Hodgkin lymphoma survivor. <i>American Journal of Medicine</i> , 2011 , 124, 1106-12	2.4	10
17	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2011 , 86, 998-1000	7.1	25
16	Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1620-6	2.2	56
15	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment in a Single Institution Experience. <i>Blood</i> , 2011 , 118, 1580-1580	2.2	1
14	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2011 , 118, 2656-2656	2.2	1
13	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. <i>Blood</i> , 2011 , 118, 3652-3652	2.2	
12	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. <i>Blood</i> , 2011 , 118, 1926-1926	2.2	
11	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. <i>Blood</i> , 2011 , 118, 3642-3642	2.2	
10	Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. <i>Annals of Oncology</i> , 2010 , 21, 2262-2266	10.3	122
9	Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. <i>American Journal of Hematology</i> , 2010 , 85, 171-3	7.1	54
8	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2010 , 116, 287-287	2.2	0
7	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes in a Single Institution Experience. <i>Blood</i> , 2010 , 116, 4168-4168	2.2	0

6	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010 , 116, 996-996	2.2	2
5	Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. <i>American Journal of Hematology</i> , 2009 , 84, 795-8	7.1	4 ⁰
4	Pure red cell aplasia and thymoma. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 263-4	8.9	8
3	Perioperative Outcome of Patients with Acquired Factor X Deficiency Associated with AL Amyloidosis: The Mayo Clinic Experience.. <i>Blood</i> , 2007 , 110, 3965-3965	2.2	1
2	Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. <i>British Journal of Haematology</i> , 2006 , 135, 405-7	4.5	7 ⁸
1	Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic Lymphoma.. <i>Blood</i> , 2006 , 108, 2396-2396	2.2	